LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial-Reference-Cited by-同舟云学术

LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

Published:2020-09 Issue: Volume:31 Page:S1178-S1179
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Faivre-Finn C.,Vicente D.,Kurata T.,Planchard D.,Paz-Ares L.,Vansteenkiste J.F.,Spigel D.R.,Garassino M.C.,Reck M.,Senan S.,Naidoo J.,Rimner A.,Wu Y-L.,Gray J.E.,Özgüroğlu M.,Lee K.H.,Newton M.,Wang L.,Thiyagarajah P.,Antonia S.J.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer;Thoracic Cancer;2023-11-14

2. Hormetic and synergistic effects of cancer treatments revealed by modelling combinations of radio - or chemotherapy with immunotherapy;BMC Cancer;2023-10-27

3. Optimization of diagnostic and therapeutic management in patients with stage III non-small cell lung cancer — experience of the centers in Poznań;Oncology in Clinical Practice;2023-06-29

4. Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis;Journal of Oncology;2023-01-13

5. Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity;Cancers;2022-06-30